Physician profile
Khalid Javed
NPI 1174529663
$3,425.64
in general payments reported to CMS, 2019-2025
28 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $264 · 2021: $405 · 2022: $869 · 2023: $551 · 2024: $142 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.08 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $351.06 | 2019-2023 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $296.04 | 2021-2025 | |
| Amarin Pharma, INC. | $278.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $274.62 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Mylan Specialty L.P. | $251.69 | 2019-2022 | |
| Novo Nordisk INC | $220.79 | 2020-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $202.15 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $148.33 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.87 | 2019 | |
| Horizon Therapeutics Plc | $94.99 | 2019 | |
| Pfizer INC. | $93.63 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.80 | 2022 | |
| Lilly USA, LLC | $74.95 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $48.17 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $46.15 | 2022 | |
| Abbott Laboratories | $36.32 | 2022-2023 | Freestyle Libre 3 |
| Sun Pharmaceutical Industries INC. | $34.93 | 2025 | |
| Dexcom, INC. | $34.62 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $34.39 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $32.20 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.63 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $26.25 | 2022 | |
| Alkermes, INC. | $25.66 | 2025 | Vivitrol |
| Braeburn INC. | $16.89 | 2024 | Brixadi |
| Ucb, INC. | $15.71 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.99 | 2025 | Voquezna |
| Amgen INC. | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.